Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Director · Chief Executive Officer | September 22, 2026 | September 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date September 22, 2026 · Filed September 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,050,249 |
Ending reported balance
After 2026-09-22 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-22 · Sale · Disposed 1,000 · Balance 1,074,249 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F2: This transaction was executed in multiple trades at prices ranging from $77.75 to $78.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 2 · 2026-09-22 · Sale · Disposed 2,000 · Balance 1,072,249 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F3: This transaction was executed in multiple trades at prices ranging from $79.11 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 3 · 2026-09-22 · Sale · Disposed 9,300 · Balance 1,062,949 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F4: This transaction was executed in multiple trades at prices ranging from $80.28 to $81.27, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 4 · 2026-09-22 · Sale · Disposed 9,900 · Balance 1,053,049 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F5: This transaction was executed in multiple trades at prices ranging from $81.28 to $82.25 inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 5 · 2026-09-22 · Sale · Disposed 2,800 · Balance 1,050,249 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F6: This transaction was executed in multiple trades at prices ranging from $82.28 to $82.53, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 27 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 27 F7: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 213,250 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 213,250 F8: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 71,644 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 71,644 F9: The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $77.75 to $78.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: This transaction was executed in multiple trades at prices ranging from $79.11 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4: This transaction was executed in multiple trades at prices ranging from $80.28 to $81.27, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5: This transaction was executed in multiple trades at prices ranging from $81.28 to $82.25 inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6: This transaction was executed in multiple trades at prices ranging from $82.28 to $82.53, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F7: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
F8: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
F9: The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2020 Filed Sep 3, 2020 22:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,014 | $114.74 | $345,827.26 |
DisclosureSEC source: 0001209191-20-049523 · doc4.xml · nonDerivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 967,381 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $114.37 to $115.28. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,086 | $113.82 | $578,892.08 |
DisclosureSEC source: 0001209191-20-049523 · doc4.xml · nonDerivative · entry 5 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 970,395 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $113.35 to $114.33. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,700 | $112.86 | $191,865.91 |
DisclosureSEC source: 0001209191-20-049523 · doc4.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 975,481 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $112.28 to $113.25. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 14,000 | $1.07 | $14,980.00 |
DisclosureSEC source: 0001209191-20-049523 · doc4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 977,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This option exercise was not effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 7,360 | $5.04 | $37,094.40 |
DisclosureSEC source: 0001209191-20-049523 · doc4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 963,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 2,640 | $1.20 | $3,168.00 |
DisclosureSEC source: 0001209191-20-049523 · doc4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 955,821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:56 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-20-045160 · doc4.xml · derivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,125 Underlying: Class A Common Stock · 10,000 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · derivative.exercise_date: This option, originally for 250,000 shares, of which 106,875 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:56 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $101.31 | $10,131.00 |
DisclosureSEC source: 0001209191-20-045160 · doc4.xml · nonDerivative · entry 5 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953,181 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:56 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 700 | $100.63 | $70,440.02 |
DisclosureSEC source: 0001209191-20-045160 · doc4.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953,281 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $100.30 to $101.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:56 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 6,100 | $99.38 | $606,208.24 |
DisclosureSEC source: 0001209191-20-045160 · doc4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953,981 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $99.09 to $100.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:56 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,100 | $98.87 | $306,496.38 |
DisclosureSEC source: 0001209191-20-045160 · doc4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 960,081 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $98.09 to $99.08. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:56 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $5.04 | $50,400.00 |
DisclosureSEC source: 0001209191-20-045160 · doc4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 963,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| July 01, 2020 Filed Jul 3, 2020 00:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-20-040746 · doc4.xml · derivative · entry 5 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,125 Underlying: Class A Common Stock · 10,000 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · derivative.exercise_date: This option, originally for 250,000 shares, of which 96,875 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| July 01, 2020 Filed Jul 3, 2020 00:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $88.88 | $26,664.99 |
DisclosureSEC source: 0001209191-20-040746 · doc4.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953,181 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $88.72 to $89.08. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2020 Filed Jul 3, 2020 00:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,500 | $87.99 | $395,946.90 |
DisclosureSEC source: 0001209191-20-040746 · doc4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953,481 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $87.62 to $88.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2020 Filed Jul 3, 2020 00:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,200 | $87.16 | $453,227.84 |
DisclosureSEC source: 0001209191-20-040746 · doc4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 957,981 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $86.62 to $87.61. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2020 Filed Jul 3, 2020 00:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $5.04 | $50,400.00 |
DisclosureSEC source: 0001209191-20-040746 · doc4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 963,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:57 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-20-034169 · doc4.xml · derivative · entry 8 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,125 Underlying: Class A Common Stock · 10,000 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · derivative.exercise_date: This option, originally for 250,000 shares, of which 86,875 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:57 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $81.97 | $40,985.00 |
DisclosureSEC source: 0001209191-20-034169 · doc4.xml · nonDerivative · entry 7 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953,181 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $81.95 to $82.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:57 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,500 | $81.51 | $285,301.45 |
DisclosureSEC source: 0001209191-20-034169 · doc4.xml · nonDerivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953,681 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $80.95 to $81.93. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:57 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,100 | $80.14 | $88,149.05 |
DisclosureSEC source: 0001209191-20-034169 · doc4.xml · nonDerivative · entry 5 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 957,181 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $79.79 to $80.63. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:57 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,700 | $79.35 | $134,887.69 |
DisclosureSEC source: 0001209191-20-034169 · doc4.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 958,281 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $78.78 to $79.76. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:57 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,100 | $78.11 | $164,031.00 |
DisclosureSEC source: 0001209191-20-034169 · doc4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 959,981 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $77.62 to $78.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:57 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,100 | $77.17 | $84,887.99 |
DisclosureSEC source: 0001209191-20-034169 · doc4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 962,081 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $76.61 to $77.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:57 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $5.04 | $50,400.00 |
DisclosureSEC source: 0001209191-20-034169 · doc4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 963,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| May 19, 2020 Filed May 20, 2020 21:54 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030990 · doc4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953,181 Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:54 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 9,167 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-20-027175 · doc4.xml · derivative · entry 7 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,125 Underlying: Class A Common Stock · 9,167 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · derivative.exercise_date: This option, originally for 250,000 shares, of which 76,875 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:54 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 833 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001209191-20-027175 · doc4.xml · derivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,250 Underlying: Class A Common Stock · 833 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · derivative.exercise_date: This option, originally for 300,000 shares, of which 168,750 have been exercised, vested as to one-forty-eighth of the shares on October 1, 2017, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:54 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,502 | $78.72 | $196,963.44 |
DisclosureSEC source: 0001209191-20-027175 · doc4.xml · nonDerivative · entry 5 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 954,681 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $78.39 to $79.20. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:54 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,197 | $77.66 | $170,609.57 |
DisclosureSEC source: 0001209191-20-027175 · doc4.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 957,183 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $77.23 to $78.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:54 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,301 | $76.65 | $406,339.14 |
DisclosureSEC source: 0001209191-20-027175 · doc4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 959,380 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $76.19 to $77.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:54 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 9,167 | $5.04 | $46,201.68 |
DisclosureSEC source: 0001209191-20-027175 · doc4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 964,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:54 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 833 | $1.20 | $999.60 |
DisclosureSEC source: 0001209191-20-027175 · doc4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 955,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 20:48 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 235,733 | $0.00 Strike: $74.58 | $0.00 |
DisclosureSEC source: 0001209191-20-025444 · doc4.xml · derivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,733 Underlying: Class A Common Stock · 235,733 shares Expires 2030-04-21 F1 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one forty-eighth of the shares on May 1, 2020 and each month thereafter, subject to the reporting person continuing as a service provider through each such date. Read SEC document |
| April 06, 2020 Filed Apr 7, 2020 20:43 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 4,167 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001209191-20-023792 · doc4.xml · derivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Class A Common Stock · 4,167 shares Expires 2026-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, originally for 200,000 shares, of which 183,333 have been exercised, vested as to one-fourth of the shares on August 1, 2017, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| April 06, 2020 Filed Apr 7, 2020 20:43 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 4,167 | $1.07 | $4,458.69 |
DisclosureSEC source: 0001209191-20-023792 · doc4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 954,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001209191-20-023288 · doc4.xml · derivative · entry 5 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,083 Underlying: Class A Common Stock · 10,000 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · derivative.exercise_date: This option, originally for 300,000 shares, of which 167,917 have been exercised, vested as to one-forty-eighth of the shares on October 1, 2017, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $59.82 | $11,964.00 |
DisclosureSEC source: 0001209191-20-023288 · doc4.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 950,514 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $59.80 to $59.84. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,716 | $58.34 | $275,137.10 |
DisclosureSEC source: 0001209191-20-023288 · doc4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 950,714 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $58.02 to $58.84. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,084 | $57.76 | $293,643.71 |
DisclosureSEC source: 0001209191-20-023288 · doc4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 955,430 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $57.02 to $58.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $1.20 | $12,000.00 |
DisclosureSEC source: 0001209191-20-023288 · doc4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 960,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| March 24, 2020 Filed Mar 25, 2020 22:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001209191-20-021171 · doc4.xml · derivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,834 Underlying: Class A Common Stock · 12,500 shares Expires 2026-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, originally for 200,000 shares, of which 179,166 have been exercised, vested as to one-fourth of the shares on August 1, 2017, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 24, 2020 Filed Mar 25, 2020 22:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 12,500 | $1.07 | $13,375.00 |
DisclosureSEC source: 0001209191-20-021171 · doc4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 950,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 1,667 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001209191-20-017554 · doc4.xml · derivative · entry 12 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,083 Underlying: Class A Common Stock · 1,667 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F11 · derivative.exercise_date: This option, originally for 300,000 shares, of which 157,917 have been exercised, vested as to one-fourth of the shares on October 1, 2017, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 8,333 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001209191-20-017554 · doc4.xml · derivative · entry 11 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,334 Underlying: Class A Common Stock · 8,333 shares Expires 2026-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F10 · derivative.exercise_date: This option, originally for 200,000 shares, of which 166,666 have been exercised, vested as to one-fourth of the shares on August 1, 2017, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 447 | $70.01 | $31,292.55 |
DisclosureSEC source: 0001209191-20-017554 · doc4.xml · nonDerivative · entry 10 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 938,014 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · price: This transaction was executed in multiple trades at prices ranging from $69.78 to $70.33. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 822 | $69.34 | $56,999.86 |
DisclosureSEC source: 0001209191-20-017554 · doc4.xml · nonDerivative · entry 9 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 938,461 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $68.70 to $69.55. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 618 | $68.13 | $42,103.41 |
DisclosureSEC source: 0001209191-20-017554 · doc4.xml · nonDerivative · entry 8 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 939,283 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $67.69 to $68.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $66.86 | $40,116.00 |
DisclosureSEC source: 0001209191-20-017554 · doc4.xml · nonDerivative · entry 7 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 939,901 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $66.65 to $67.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 800 | $65.79 | $52,628.00 |
DisclosureSEC source: 0001209191-20-017554 · doc4.xml · nonDerivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 940,501 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $65.51 to $66.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.